Viral recombination another way HIV fools the immune systemJuly 22, 2008
When individuals infected with HIV become infected with a second strain of the virus, the two viral strains can exchange genetic information, creating a third, recombinant strain of the virus. It is known that the presence of multiple viral strains, called superinfection, frequently leads to a loss of immune control of viral levels. Now a study from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) shows that how and where viral strains swap DNA may be determined by the immune response against the original infecting strain. Their report will appear in the Journal of Experimental Medicine and has been released online.
"The implication that recombination events are selected by immune responses identifies a new mechanism for the virus to escape the patient's immune system, which would present additional challenges to vaccine design," says Hendrik Streeck, MD, PhD, of PARC/MGH, one of the paper's lead authors. "This finding also has worldwide implications for the development of more complex strains of HIV."
Part of the immune system's response against HIV is carried out by HIV-specific CD8 T cells, also called cytotoxic T lymphocytes (CTLs), which can identify and kill virus-infected cells. Previous PARC/MGH research showed that the effectiveness of the CTL response varies depending on which version or allele of an immune system molecule called HLA Class I an individual has inherited. The current study was undertaken to investigate why an HIV-positive research participant known to have a powerfully protective Class I allele called HLA-B27 began to experience rapid increases in viral levels much sooner than would have been expected.
An examination of blood samples from this individual revealed that his immune response against HIV had predictably controlled the virus for about a year and a half after he was first diagnosed. The effective CTL response was primarily directed against a short segment of the Gag protein typically targeted in HLA-B27 patients.
Analysis after the abrupt increase in viral levels showed that the patient had become infected with a second strain of HIV, and two months later it was found that the two strains had exchanged portions of their Gag sequences initially targeted by his CTLs, allowing the virus to escape from that immune response. The patient's viral loads stabilized for a while but rose again several months later, when it was found that a second HIV mutation that more effectively evades control by HLA-B27 had developed, possibly in response to a second recombination of viral sequences.
"The first Gag recombination event facilitated escape from the primary immune response, shortly after which the immune response recovered to recognize this mutant strain," Streeck explains. "After the second recombination event and emergence of a more potent mutation, there was a dramatic reduction in the CTL response against both versions, leading to a significant increase in viral loads."
Todd Allen, PhD, of PARC-MGH, the study's senior author adds that, while recombination itself appears to be a random event, recombinant strains that are better able to evade the immune system are likely to become dominant through natural selection. He also stresses that even patients whose immune systems can partially control HIV should avoid a secondary infection that could lead to the development of an uncontrollable, recombinant viral strain.
Streeck notes, "Given the growing frequency of recombinant HIV strains worldwide, we need to better understand how immune system pressures may be driving their development and also determine how frequently patients exposed to a second strain of HIV become superinfected." He is a research fellow in Medicine at Harvard Medical School, where Allen is an associate professor of Medicine.
Massachusetts General Hospital
Related Immune System Current Events and Immune System News Articles
Geisel Researchers Contribute to Study of Trained Immunity
A study published in the journal Science provides support for a new-and still controversial-understanding of the immune system.
Cells from placentas safe for patients with multiple sclerosis
Patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published today in the journal Multiple Sclerosis and Related Disorders.
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
Studies report new findings on treatment options for mesothelioma
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.
Scientists Identify the Signature of Aging in the Brain
How the brain ages is still largely an open question - in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems.
Genetic 'instruction set' for antibodies knocks down hepatitis C in mice
A triple-punch of antibodies both prevented hepatitis C infection and wiped out the disease after it had established itself in laboratory mice, according to a study led by Princeton University researchers.
Spot on against autoimmune diseases and chronic inflammations
Multiple sclerosis, type 1 diabetes and lupus have one thing in common: They are all autoimmune diseases in which the immune cells can no longer differentiate between friend or foe and thus attack the body's own tissue.
Immune activity shortly after surgery holds big clue to recovery rate, Stanford team finds
The millions of people who undergo major surgery each year have no way of knowing how long it will take them to recover from the operation.
Findings give hope to plant extract as possible lupus treatment
New findings by a biomedical engineer and his team at the University of Houston (UH) raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.
A wriggly solution to a first-world problem
Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease.
More Immune System Current Events and Immune System News Articles